Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Nov 12, 2019 • 8:30 AM EST
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Nov 8, 2019 • 8:30 AM EST
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Nov 7, 2019 • 8:30 AM EST
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
Nov 13, 2019 • 3:30pm EST
See all events
Nov 5, 2019 • 4:30pm EST
Sep 10, 2019 • 8:45am EST
New York City